Adverum Biotechnologies Inc (ADVM)
11.30
+0.15
(+1.35%)
USD |
NASDAQ |
Apr 19, 16:00
11.30
0.00 (0.00%)
After-Hours: 20:00
Adverum Biotechnologies Cash from Operations (TTM): -90.90M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -90.90M |
September 30, 2023 | -88.05M |
June 30, 2023 | -95.94M |
March 31, 2023 | -101.57M |
December 31, 2022 | -108.09M |
September 30, 2022 | -115.43M |
June 30, 2022 | -109.42M |
March 31, 2022 | -114.46M |
December 31, 2021 | -107.83M |
September 30, 2021 | -104.24M |
June 30, 2021 | -104.99M |
March 31, 2021 | -87.98M |
December 31, 2020 | -79.29M |
September 30, 2020 | -71.90M |
June 30, 2020 | -54.89M |
March 31, 2020 | -49.57M |
December 31, 2019 | -49.17M |
September 30, 2019 | -47.06M |
June 30, 2019 | -54.44M |
March 31, 2019 | -54.20M |
December 31, 2018 | -53.96M |
Date | Value |
---|---|
September 30, 2018 | -53.43M |
June 30, 2018 | -46.52M |
March 31, 2018 | -46.59M |
December 31, 2017 | -45.42M |
September 30, 2017 | -41.56M |
June 30, 2017 | -41.23M |
March 31, 2017 | -38.03M |
December 31, 2016 | -38.37M |
September 30, 2016 | -39.15M |
June 30, 2016 | -38.72M |
March 31, 2016 | -39.75M |
December 31, 2015 | -35.34M |
September 30, 2015 | -31.27M |
June 30, 2015 | -27.02M |
March 31, 2015 | -12.04M |
December 31, 2014 | -5.648M |
September 30, 2014 | -1.314M |
June 30, 2014 | 3.069M |
March 31, 2014 | -3.378M |
December 31, 2013 | -2.175M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-115.43M
Minimum
Sep 2022
-47.06M
Maximum
Sep 2019
-86.06M
Average
-90.90M
Median
Dec 2023
Cash from Operations (TTM) Benchmarks
Karyopharm Therapeutics Inc | -92.72M |
Ardelyx Inc | -89.72M |
Minerva Neurosciences Inc | -14.78M |
Arcutis Biotherapeutics Inc | -247.06M |
4D Molecular Therapeutics Inc | -75.79M |